Comanche is a biopharmaceutical company developing an investigational siRNA medicine for preterm preeclampsia. We envision a world where all women and their babies have access to safe and effective therapies for treating life threatening complications of pregnancy, and those solutions must be evidence-based and affordable.
Pretzel Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction. Founded by leading experts in mitochondrial biology, the company aims to create innovative treatments that address the underlying causes of mitochondrial issues. By leveraging a comprehensive understanding of mitochondrial mechanisms, Pretzel Therapeutics seeks to reverse dysfunction at its roots, potentially providing effective solutions for patients suffering from a range of conditions, including those related to aging. The company's name reflects its scientific focus on the mitochondrion, which is characterized by its unique and highly folded inner membrane, distinguishing it from other organelles in the body.
Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.
Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.
OMass Technologies Ltd engages in drug discovery by applying mass spectrometry to the characterization of intact protein assemblies. The company offers biotherapeutics, membrane proteins, drug binding, and purifications guiding services. In addition, OMass Technologies Ltd offers structural mass spectrometry (MS) platforms, often referred to as native mass spectrometry, for characterizing complex protein assemblies. The company assists biotechnology and pharmaceutical companies in tackling drug targets and biotherapeutics. OMass Technologies Ltd was founded in 2016 and is based in Begbroke, United Kingdom.
Waltz Health operates in the pharmaceutical supply chain, focusing on creating innovative, technology-driven solutions for pricing, distribution, and prescription of medications. The company develops consumer tools aimed at guiding decisions related to prescription care, with a particular emphasis on the needs of both payers and consumers. By utilizing AI-driven marketplaces, Waltz Health seeks to reduce costs and enhance the decision-making process for users. Their offerings provide better pricing information and resources that empower consumers while assisting payers in managing their pharmacy benefits more effectively.
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
The Pill Club is a healthcare service that specializes in delivering birth control and related products across the United States. Founded in 2014 and based in California, it operates as an online retailer and pharmacy, providing a convenient way for women to access birth control, emergency contraceptives, and wellness gifts. The Pill Club is supported by a team of medical professionals and aims to empower women by facilitating personalized healthcare experiences. It offers prescription services in 34 states and Washington D.C., ensuring widespread access to its products. With a focus on women's health and well-being, the company strives to enhance personal freedom and health ownership through its innovative telemedicine approach.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Resilience is a biopharmaceutical manufacturing and technology company based in La Jolla, California, established in 2020. It aims to enhance access to complex medicines and safeguard biopharmaceutical supply chains. The company specializes in end-to-end manufacturing and development solutions across various therapeutic modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. Resilience provides customized manufacturing capabilities that cater to the diverse needs of biopharmaceuticals at all stages of the drug development process, from pre-clinical development to commercial supply. With a focus on developing new manufacturing technologies, Resilience ensures high-quality and regulatory-compliant processes for complex and novel medicines.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
scPharmaceticals is creating innovative and important new therapeutic options by administering drugs subcutaneously using a convenient two component delivery system suitable for patient self-administration.In February 2013 scPharmaceuticals was formed to continue the groundbreaking work of SpringLeaf Therapeutics, a Boston area company that started in 2007. scPharmaceuticals targets the untapped opportunity of treating patients with serious medical conditions with a convenient safe and comfortable subcutaneous administration of a drug. This is therapeutically equivalent to intravenous administration while avoiding the cost, burden and risks associated with intravenous administration.
ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
PACT Pharma, Inc. is engaged in developing personalized cell-based therapies aimed at treating cancer, specifically through neoantigen-specific adoptive TCR T-cell therapies for solid tumors. The company utilizes advanced bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying neoantigen peptides that provoke targeted T cell responses against cancer cells. By recognizing neo-epitopes, which are unique mutations in each patient's cancer, PACT Pharma creates autologous T cells engineered to specifically target and eliminate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is focused on innovative approaches to enhance cancer treatment through tailored immunotherapies.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
Verve Therapeutics is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to provide lifelong protection against coronary artery disease, a leading global cause of mortality. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company employs gene-editing technology to create treatments that shift the management of cardiovascular diseases from chronic care to potentially curative interventions. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are recognized for their roles in regulating blood lipids, specifically low-density lipoprotein cholesterol. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance delivery technologies for its cardiovascular treatments.
Arrakis Therapeutics is a biopharmaceutical company focused on developing innovative drugs that target ribonucleic acid (RNA) to treat a variety of diseases, including cancer and rare genetic disorders. The company employs a unique drug discovery platform that integrates advanced RNA bioinformatics and structural tools, allowing it to identify new RNA targets and create RNA-targeted small molecules (rSMs). Its proprietary pipeline consists of these rSMs aimed at genetically validated targets across multiple disease areas. Additionally, Arrakis offers SHAPEware, a software tool that assists in predicting RNA secondary structures and potential ligand-binding sites. Founded in 2015 and based in Waltham, Massachusetts, Arrakis Therapeutics aims to enhance therapeutic options for patients through its cutting-edge research and development efforts.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
The Pill Club is a healthcare service that specializes in delivering birth control and related products across the United States. Founded in 2014 and based in California, it operates as an online retailer and pharmacy, providing a convenient way for women to access birth control, emergency contraceptives, and wellness gifts. The Pill Club is supported by a team of medical professionals and aims to empower women by facilitating personalized healthcare experiences. It offers prescription services in 34 states and Washington D.C., ensuring widespread access to its products. With a focus on women's health and well-being, the company strives to enhance personal freedom and health ownership through its innovative telemedicine approach.
Schrödinger is a healthcare software company that specializes in computational drug design, serving the biopharmaceutical and biotechnology sectors. Founded in 1990, the company operates through two main segments: Software and Drug Discovery. Its software solutions facilitate drug discovery processes for pharmaceutical and industrial clients, as well as academic and governmental research institutions. In addition to software sales, Schrödinger engages in drug discovery through its own preclinical and clinical programs, often collaborating with other organizations. The company is committed to advancing its computational platform by investing in scientific research and talent, and it has established partnerships and collaborations across more than 70 countries. With a workforce of over 400 employees, Schrödinger continues to influence the life sciences and materials science industries through innovative approaches to drug discovery.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
PACT Pharma, Inc. is engaged in developing personalized cell-based therapies aimed at treating cancer, specifically through neoantigen-specific adoptive TCR T-cell therapies for solid tumors. The company utilizes advanced bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying neoantigen peptides that provoke targeted T cell responses against cancer cells. By recognizing neo-epitopes, which are unique mutations in each patient's cancer, PACT Pharma creates autologous T cells engineered to specifically target and eliminate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is focused on innovative approaches to enhance cancer treatment through tailored immunotherapies.
FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.
Celsius Therapeutics is a biotechnology company focused on developing innovative medicines to treat complex diseases, including autoimmunity and cancer. Founded in 2017 and based in Cambridge, Massachusetts, the company leverages advanced techniques such as single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. By systematically applying single-cell sequencing and analyzing extensive datasets with sophisticated algorithms, Celsius Therapeutics aims to discover critical biomarkers and precision therapies that enhance patient care and enable clinicians to identify genes that play a causal role in various conditions.
Insitro, Inc. is a data-driven drug discovery and development company based in South San Francisco, California, founded in 2018. The company utilizes machine learning and high-throughput biology to transform the traditional processes of drug discovery and delivery. By generating extensive functional genomic datasets and aligning them with patient data through innovative machine learning techniques, Insitro builds predictive models that aim to address critical challenges in pharmaceutical research and development. These models facilitate accelerated target selection and the design of effective therapeutics, ultimately enhancing the efficiency of drug development and informing clinical strategies. The focus of Insitro's work includes the treatment of nonalcoholic steatohepatitis (NASH), showcasing its commitment to addressing significant health issues through advanced technology.
Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.
Vaccitech Limited is a biotechnology company based in Oxford, United Kingdom, that focuses on researching and developing T cell immunotherapeutic products and vaccines. Established in 2016 as a spin-out from the University of Oxford’s Jenner Institute, the company specializes in viral vector vaccines designed to address significant health challenges, including hepatitis B, human papillomavirus, and prostate cancer. Vaccitech utilizes advanced chimpanzee adenovirus technology to elicit robust T-cell responses, fostering lasting cell-mediated immunity. The company has progressed its assets into clinical trials, showing promising initial results. Upcoming studies include a phase IIB efficacy trial for a universal influenza vaccine targeting individuals aged 65 and older, as well as an extended phase I trial for prostate cancer treatment, reflecting Vaccitech's commitment to advancing innovative therapeutic solutions.
RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, specializing in the discovery and development of oral small molecule therapies for oncology and inflammatory diseases. The company is focused on addressing significant unmet medical needs through its proprietary discovery engine. Its lead oncology candidate, FLX475, is a C-C motif chemokine receptor 4 antagonist currently undergoing Phase 2 clinical trials, both as a monotherapy and in combination with pembrolizumab, for various tumor types. Additionally, RAPT's lead inflammation drug candidate, RPT193, aims to selectively inhibit the migration of type 2 T helper cells into allergically inflamed tissues. The company is also exploring other potential targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1, which are in the discovery phase. Founded in 2015, RAPT Therapeutics was previously known as FLX Bio, Inc. before its name change in May 2019.
Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, focused on transforming the drug discovery process, particularly in targeted oncology. The company employs an innovative allosteric drug-discovery platform that integrates computational techniques with experimental methods to analyze protein motion and interactions. This approach aids in the development of therapies for complex diseases, including cancer. Relay's product candidates include RLY-1971, an oral small molecule inhibitor targeting SHP2, currently undergoing Phase 1 trials for advanced solid tumors; RLY-4008, a selective inhibitor of FGFR2 for tumors with specific oncogenic alterations; and RLY-PI3K1047, which targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, Relay Therapeutics is dedicated to enhancing small molecule therapeutic discovery through its advanced platform and targeted treatment strategies.
Obsidian Therapeutics develops innovative cell and gene therapies aimed at enhancing adoptive immunotherapy for cancer patients. Founded in 2015 and based in Cambridge, Massachusetts, the company focuses on creating next-generation therapies that utilize pharmacologic operating systems to provide precise control over protein activity within cells. This technology allows for the development of adoptive cell therapies with advanced functionalities that can be managed by physicians using simple, safe, and orally active medications. By offering improved control over treatment, Obsidian Therapeutics aims to provide better outcomes for patients compared to existing cell therapy options.
LifeMine Therapeutics, Inc. is a biotechnology company focused on discovering new drug modalities from eukaryotic microbes, particularly fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, the company employs an integrated, genomically-enabled drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine aims to elucidate human biology and develop innovative therapeutics that target the underlying causes of serious diseases. By mining fungal biodiversity, the company seeks to create novel therapeutics designed to tackle previously intractable medical challenges, ultimately enhancing treatment options for healthcare providers.
Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Evelo Biosciences is a biotechnology company focused on developing oral biologics, specifically monoclonal microbials, for treating a range of inflammatory diseases and cancers. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company is advancing several candidates through various stages of clinical development. EDP1815, currently in a Phase 1b clinical study, aims to treat psoriasis and atopic dermatitis, while other candidates in pre-clinical stages target conditions such as psoriatic arthritis, asthma, and neuro-inflammatory diseases. Additionally, EDP1503 is undergoing Phase 1/2 trials for colorectal cancer and other malignancies. By utilizing naturally occurring monoclonal microbials, Evelo seeks to revolutionize drug discovery and development, offering a new approach to modulating systemic immunology and biology through oral delivery. This innovative platform has the potential to enhance the efficiency and effectiveness of treatments across various health conditions.
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and discovering therapeutic antibodies for the treatment of solid tumors and hematological malignancies. The company's lead product candidate, CTX-471, is a fully human monoclonal antibody that acts as an agonist of CD137, currently undergoing Phase I clinical trials for patients who have had inadequate responses to existing PD-1/PD-L1 checkpoint inhibitors. In addition to CTX-471, Compass is advancing several preclinical assets, including CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, and CTX-8573, designed to engage natural killer (NK) cells against B cell maturation antigen, which is prevalent in multiple myeloma. Founded in 2014, Compass Therapeutics is headquartered in Cambridge, Massachusetts, and employs innovative platforms to enhance the efficacy of its antibody therapeutics.
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative therapies for genetically defined diseases with high unmet medical needs. The company's lead product candidate, losmapimod, is a small molecule currently undergoing Phase 2b clinical trials for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a progressive muscle-wasting disorder. Another key candidate, FTX-6058, aims to increase fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia. In addition to these programs, Fulcrum is exploring drug targets for other conditions such as Duchenne muscular dystrophy, Friedreich ataxia, myotonic dystrophy 1, and various neurological and pulmonary diseases. The company has established collaborations with Acceleron Pharma and MyoKardia to advance research and develop targeted therapies for pulmonary diseases and genetic cardiomyopathies, respectively. Founded in 2015, Fulcrum Therapeutics is committed to improving the lives of patients facing significant health challenges.
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
ZappRx, Inc. is a digital health company based in Boston, Massachusetts, that specializes in a cloud-based platform designed to streamline the management of specialty medications. Founded in 2012, the company provides a secure online environment where healthcare providers, specialty pharmacies, and biopharma companies can collaborate efficiently. Its platform automates the prescription and prior authorization processes, facilitating communication among patients, physicians, and pharmacists while reducing reliance on traditional methods such as faxes and phone calls. By consolidating essential information related to specialty prescribing—including pharmacy details, payer requirements, and clinical history—the platform enhances the efficiency and transparency of healthcare delivery, particularly in the fields of pulmonary, cardiology, and gastroenterology. ZappRx operates as a subsidiary of Allscripts Healthcare Solutions, Inc. as of June 2019.
Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
PACT Pharma, Inc. is engaged in developing personalized cell-based therapies aimed at treating cancer, specifically through neoantigen-specific adoptive TCR T-cell therapies for solid tumors. The company utilizes advanced bioinformatics to analyze patients' tumor and normal DNA and RNA, identifying neoantigen peptides that provoke targeted T cell responses against cancer cells. By recognizing neo-epitopes, which are unique mutations in each patient's cancer, PACT Pharma creates autologous T cells engineered to specifically target and eliminate tumors expressing these neo-antigens. Founded in 2016 and headquartered in South San Francisco, California, PACT Pharma is focused on innovative approaches to enhance cancer treatment through tailored immunotherapies.
Carrick Therapeutics, Ltd., founded in 2015 and based in Dublin, Ireland, focuses on developing innovative cancer therapeutics aimed at transforming cancer treatment. The company targets specific molecular pathways associated with aggressive and resistant cancer forms, allowing for early detection of predictive biomarkers. This approach facilitates timely treatment initiation for patients, enhancing the potential for improved outcomes in cancer care.
ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.
Oration PBC is a cloud-based platform that offers prescription savings services to individuals and organizations across the United States. The platform facilitates the management of prescription transactions and provides users with pricing information for their medications. Additionally, it analyzes prescription claims from companies, delivering solutions that help both businesses and employees reduce their prescription expenses. Established in 2014 and headquartered in Foster City, California, Oration PBC has gained significant traction in the healthcare sector, analyzing over one billion dollars in healthcare transactions in collaboration with major corporations. The company aims to address the complexities of the American healthcare system by creating impactful solutions for its users.
TinyRx was an on-demand prescription delivery service operating in the Bay Area. It shut down in May 2016.
Zephyr Health, Inc. specializes in providing insights-as-a-service solutions tailored for life sciences companies. Its primary product, Zephyr Illuminate, is a cloud-based platform that integrates global health data to assist pharmaceutical, biotechnology, and medical device firms in making informed decisions throughout the product lifecycle. The company's offerings include various analytics solutions such as Referral Analytics, which identifies patterns in healthcare provider referrals; Segment Analytics, which compiles data relevant to medical and commercial teams; and Zephyr Recommendations, which enhances engagement with targeted physicians and institutions. Additional tools include Zephyr Profiles, providing comprehensive customer profiles; Zephyr Scores, which benchmark physicians and hospitals against peers; and Zephyr Scoreboard, which tracks trends in specific segments. Founded in 2011 and based in San Francisco, Zephyr Health operates as a subsidiary of Anju Software, Inc., and has established a strategic partnership with Decision Resources Group to enhance its data and analytics capabilities.
Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.
Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.
Foundation Medicine, Inc. specializes in providing molecular information products aimed at enhancing cancer treatment through genomic insights. The company utilizes proprietary methods and algorithms to analyze cancer specimens, helping physicians tailor treatments based on the unique genetic profile of each patient's tumor. Its product offerings include FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies, and various diagnostic assays such as FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine develops a knowledgebase called FoundationCORE to disseminate scientific advancements within the oncology community. The company collaborates with major pharmaceutical firms and research organizations to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc. It aims to transform cancer care by enabling personalized treatment strategies informed by detailed genomic profiling.
Predilytics, Inc. is a healthcare information technology company that specializes in providing analytical solutions to health plans, providers, and other entities involved in risk management. Founded in 2011 and headquartered in Burlington, Massachusetts, the company utilizes advanced machine-learning tools to analyze both structured and unstructured data, along with external data sources, to generate actionable insights. Its offerings include Consumer Acquisition and Retention solutions that help organizations understand consumer behavior to enhance product design and member retention. Additionally, Predilytics provides Care Directions solutions to identify high-risk members who are most likely to benefit from care management, a Risk Adjustment solution aimed at optimizing risk adjustment activities for better reimbursement and care quality, and Quality Insight solutions to identify quality improvement opportunities. As of 2015, Predilytics operates as a subsidiary of Welltok, Inc.
Foundation Medicine, Inc. specializes in providing molecular information products aimed at enhancing cancer treatment through genomic insights. The company utilizes proprietary methods and algorithms to analyze cancer specimens, helping physicians tailor treatments based on the unique genetic profile of each patient's tumor. Its product offerings include FoundationOne for solid tumors, FoundationOne Heme for hematologic malignancies, and various diagnostic assays such as FoundationFocus CDxBRCA for ovarian cancer. Additionally, Foundation Medicine develops a knowledgebase called FoundationCORE to disseminate scientific advancements within the oncology community. The company collaborates with major pharmaceutical firms and research organizations to advance precision medicine and develop companion diagnostics. Founded in 2009 and headquartered in Cambridge, Massachusetts, Foundation Medicine operates as a subsidiary of Roche Holdings, Inc. It aims to transform cancer care by enabling personalized treatment strategies informed by detailed genomic profiling.
Wingu is focused on enhancing the efficiency of outsourced pharmaceutical research through a metrics-driven software platform. The company streamlines information exchange for researchers, allowing for improved collaboration and communication. Additionally, it offers project insights for managers and provides comprehensive analytics for executives, facilitating informed decision-making. By optimizing operational processes in the pharmaceutical sector, Wingu aims to support better and quicker outcomes in research and development.
iPierian is engaged in the research and development of therapies aimed at treating neurodegenerative diseases, including spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease. The company utilizes induced pluripotent stem cells to facilitate drug discovery and development, focusing on addressing significant unmet medical needs. In particular, iPierian is developing therapies and monoclonal antibodies that target Tauopathies, which are diseases characterized by the accumulation of tau protein in the brain. These therapies aim to slow the spread of tau throughout the brain, thereby inhibiting the progression of associated diseases.
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.